Last Price | 256.30 | Max Price | 285.80 |
Min Price | 218.50 | 1 Year return | -11.77 |
Avg. Target | 265.00 | Expected Return | 3.39 % |
Sector | Health Care | Subsector | Pharmaceuticals |
Sell | 1 | Rating | |
Hold | 4 | Concensus | |
Buy | 2 | ||
Annual report 2015 |
Contact info:Street: 1 DNA WayZip Code: South San City: BASEL,Country: SwitzerlandPhone: 1 650 225 5566Email: RocheIRNA@gene.comWebsite: www.roche.comCEO: Dr Severin SchwanCFO: Dr. Alan Hippe
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 61,466 | 615,670 | 9.98 % |
2020 | 58,323 | 638,104 | 9.14 % |
2021 | 62,801 | 727,997 | 8.63 % |
2022 | 63,281 | 787,317 | 8.04 % |
2023 | 0 | 0 | 0.00 % |
2008 best year, 2009 worst year for Roche
Roche inks potential $3B multi-target strategic collaboration with Shape Therapeutics
Analysts expect over 2020 rising revenue Roche
Analysts expect revenue increase Roche
Stock Roche goes ahead in Switzerland in terms of dividend yields
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
Roche's headquarter is based in BASEL,. The core activities of Roche are in the pharmaceutical sector. Roche is leaded by CEO Dr Severin Schwan The CFO of Roche the company is Dr. Alan Hippe. Over the past 10 years the global pharmaceutical companies gained around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.
The stock lost over the past 12 months at around 14 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 66 percent. Roche's revenues between 2011 and 2015 were relatively steady and moved between 45,5 billion CHFF and 48,15 billion CHFF. Roche's net results between 2011 and 2015 were relatively steady and moved between 10,48 billion CHFF and 11,04 billion CHFF.
Over the past 5 years the Swiss company paid out dividends. Over the past 5 years Roche's dividend yield was at around 38,05 percent per year. Over the period 2011-2015 Roche raised it's dividends per share each year. Based on the yearly higher dividend payments Roche is a kind of dividend aristocrat.
At the end of 2015 the company had around 88,51 thousand people employed.
At the end of 2015 the Swiss company's balance sheet was worth 75,76 billion CHFF. At the end of 2015 the total debt positon equaled 54,78 billion CHFF. This is around 72,31 percent of the total balance sheet. At the end of 2016 the Swiss company was traded with a price/earnings-ratio of around 22. So investors paid 22 times the company's 2015's EPS. Based on it's price/earnings-ratio and dividend yield the Swiss stock can be seen as a value stock.
At the end of 2015 the pharmaceutical company's market size (her number of outstanding share times the stock price) equaled around 231,98 billion CHFF. At the end of 2015 the Swiss company had around 851 million stocks listed.
All Roche's financial reports are available here. More information about Roche can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
48,145
|
50,576
|
53,299
|
56,846
|
61,466
|
58,323
|
Costs |
39,283
|
41,001
|
44,667
|
46,347
|
47,971
|
44,029
|
Profit |
8,862
|
9,575
|
8,632
|
10,499
|
13,495
|
14,294
|
Margin of profit |
18.41
|
18.93
|
16.20
|
18.47
|
21.96
|
24.51
|
ROI |
42.24
|
40.04
|
32.65
|
38.01
|
41.21
|
39.33
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
20,979
|
23,911
|
26,441
|
27,622
|
32,747
|
36,341
|
Debt |
54,784
|
52,908
|
50,235
|
50,895
|
50,344
|
49,797
|
Total assets |
75,763
|
76,819
|
76,676
|
78,517
|
83,091
|
86,138
|
Solvency |
27.69
|
31.13
|
34.48
|
35.18
|
39.41
|
42.19
|
Cash |
9,171
|
9,107
|
11,997
|
13,118
|
11,858
|
12,334
|
Cashflow |
15,251
|
15,001
|
18,024
|
19,979
|
22,385
|
18,566
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.28
|
0.28
|
0.36
|
0.39
|
0.44
|
0.37
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
276.40
|
232.60
|
246.50
|
243.40
|
314.00
|
Eps |
11.13
|
10.04
|
12.21
|
15.62
|
16.52
|
Price/earnings-ratio |
24.83
|
23.17
|
20.19
|
15.58
|
15.51
|
Dividend |
8.20
|
8.30
|
8.70
|
9.00
|
9.10
|
Dividend % |
2.97 %
|
3.57 %
|
3.53 %
|
3.70 %
|
3.55 %
|
Payout % |
0.74
|
0.83
|
0.71
|
0.58
|
0.55
|
Book value |
34.56
|
38.11
|
39.78
|
47.07
|
52.43
|
Market to book |
0.13
|
0.16
|
0.16
|
0.19
|
0.20
|
Cashflow per stock |
21.68
|
25.98
|
28.77
|
32.17
|
26.79
|
Stocks |
692
|
694
|
694
|
696
|
693
|
Market Cap |
191.248.80
|
161.389.44
|
171.176.50
|
169.347.01
|
177.648.19
|
Date
|
Price
|
---|---|
17 Dec 2024
|
256.30
|
10 Dec 2024
|
257.20
|
06 Dec 2024
|
256.30
|
03 Dec 2024
|
256.20
|
29 Nov 2024
|
253.90
|
27 Nov 2024
|
251.40
|
13 Nov 2024
|
262.50
|
08 Nov 2024
|
265.80
|
05 Nov 2024
|
272.30
|
31 Oct 2024
|
273.50
|
29 Oct 2024
|
277.80
|
23 Oct 2024
|
272.20
|
19 Oct 2024
|
273.30
|
16 Oct 2024
|
269.60
|
14 Oct 2024
|
269.60
|
05 Oct 2024
|
258.50
|
02 Oct 2024
|
265.00
|
27 Sep 2024
|
270.60
|
20 Sep 2024
|
267.50
|
17 Sep 2024
|
264.10
|
13 Sep 2024
|
263.00
|
28 Aug 2024
|
282.00
|
26 Aug 2024
|
285.00
|
23 Aug 2024
|
282.90
|
11 Aug 2024
|
277.10
|
07 Aug 2024
|
274.20
|
05 Aug 2024
|
270.00
|
01 Aug 2024
|
285.80
|
30 Jul 2024
|
285.40
|
26 Jul 2024
|
277.50
|